Related Jobs
-
RO and SRO - Hospital Products - Leading Generics
Job Type: Permanent
Salary: Salary on application
Location: England - Essex -
Regulatory Affairs Officer/Senior Regulatory Affairs Office
Job Type: Permanent
Salary: Salary on application
Location: England - Essex
Takeda submits new drug application for cancer therapy
30 Jun 2008
Regulatory Affairs
Takeda has made a new drug application (NDA) to the Japanese authorities for its anti-cancer agent panitumumab, according to the company.
Panitumumab is for the treatment of patients with "progressed and/or relapse colorectal cancer", Takeda said.
It reported the treatment was originally developed by Amgen, which markets the medicine in the US and EU under the brand-name of Vectibix.
Masaomi Miyamoto, general manager of the pharmaceutical development division of Takeda, said: "We believe the NDA submission of panitumumab will lead to the enhancement of our oncology franchise, one of our core therapeutic areas."
Hiroyasu Nakamura, president of Takeda Bio, voiced the company's commitment to "determined engagement in the clinical development of innovative products".
Last week, Takeda announced the US Food and Drug Administration had approved its drug Velcade for use in patients with previously untreated multiple myeloma.
The company said its co-development partner, Johnson & Johnson Pharmaceutical Research & Development, has filed a corresponding application with the European Medicines Evaluation Agency (EMEA).
